Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “add” rating reissued by Numis Securities Ltd in a research note issued on Friday. They currently have a GBX 1,560 ($20.32) price objective on the stock. Numis Securities Ltd’s target price suggests a potential upside of 19.91% from the stock’s current price.
A number of other equities research analysts also recently issued reports on HIK. HSBC Holdings plc reissued a “reduce” rating and issued a GBX 1,800 ($23.44) price target on shares of Hikma Pharmaceuticals Plc in a research note on Friday, May 5th. J P Morgan Chase & Co reduced their price target on shares of Hikma Pharmaceuticals Plc from GBX 2,400 ($31.25) to GBX 1,800 ($23.44) and set a “neutral” rating on the stock in a research note on Friday, May 12th. Jefferies Group LLC downgraded shares of Hikma Pharmaceuticals Plc to an “underperform” rating and reduced their price target for the company from GBX 2,162 ($28.15) to GBX 1,450 ($18.88) in a research note on Wednesday, May 17th. Citigroup Inc. reissued a “neutral” rating and issued a GBX 1,550 ($20.18) price target on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, June 28th. Finally, Barclays PLC reissued an “overweight” rating and issued a GBX 2,200 ($28.65) price target on shares of Hikma Pharmaceuticals Plc in a research note on Monday, July 3rd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. Hikma Pharmaceuticals Plc currently has an average rating of “Hold” and an average price target of GBX 1,892.10 ($24.64).
Hikma Pharmaceuticals Plc (HIK) opened at 1293.00 on Friday. Hikma Pharmaceuticals Plc has a 52 week low of GBX 1,289.00 and a 52 week high of GBX 2,354.00. The firm has a 50-day moving average of GBX 1,426.86 and a 200-day moving average of GBX 1,781.26. The company’s market capitalization is GBX 3.12 billion.
COPYRIGHT VIOLATION NOTICE: “Hikma Pharmaceuticals Plc (LON:HIK) Given Add Rating at Numis Securities Ltd” was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2800852/hikma-pharmaceuticals-plc-lonhik-given-add-rating-at-numis-securities-ltd.html.
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.